

MORRISON & FOERSTER LLP

Attorneys at Law
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5100
Facsimile: (858) 720-5125

To: <No Name>
U.S. Patent and Trademark Office

Facsimile: 1-703-308-4556 (TC1600)

From: Kate H. Murashige

Date: April 9, 2002

FAX RECEIVED

We are transmitting a total of **36** pages (including this page).
Original or hard copy to follow if this box is checked

APR 10 2002

OFFICIAL GROUP 1600

Preparer of this slip has confirmed that facsimile number given is correct: 9111/TMP

This facsimile contains confidential information which may also be privileged. Unless you are the addressee (or authorized to receive for the addressee), you may not copy, use, or distribute it. If you have received it in error, please advise Morrison & Foerster LLP immediately by telephone or facsimile and return it promptly by mail.

Comments: Serial No. 09/853,524
Our reference: 20503-20004.20

Jf
4/12/02
NW

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231
www.uspto.gov

Application Number	Filing Date	First Named Applicant	Atty. Docket No.
09/853,524	05/10/2001	Chang, Su-Chen	205032000420

Kate H. Murashige
 Morrison & Foerster LLP
 Suite 500
 3811 Valley Centre Drive
 San Diego CA 92130-2332

Title: Adenosine as antithrombotic

Date Mailed: 03/19/2002

Request for Substitute Papers

The papers filed on 5/10/01 (certificate of mailing dated 10/19/01) are no longer in condition to become part of the permanent records of the United States Patent and Trademark Office (USPTO) for this application (37 CFR 1.52(a)) due to the United States Postal Service sanitization process.

The USPTO requests that applicant provide a copy of the above-identified papers (except for any U.S. or foreign patent documents submitted with the above-identified papers) with a statement that such copy is a complete and accurate copy of the above-identified papers (signing and returning a copy of this notice will provide such a statement). The reply to this letter should be submitted to the USPTO by facsimile at the number indicated **703-308-4556(TC1600)**.

Alternatively, the reply to this letter may be hand-carried to the Customer Service Window located in Room 1B03 of Crystal Plaza Building 2, Arlington, Virginia, 22202.

The USPTO strongly prefers that the reply to this letter be submitted by facsimile. However, if applicant cannot submit the reply to this letter by facsimile (or hand-delivery), the reply may be mailed to: Box Duplicate TC1600, U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202-2327.

This letter is not a notice under 37 CFR 1.251. However, failure to timely replay to this notice within two (2) weeks of the date of receipt of this letter may result in the USPTO issuing a notice under 37 CFR 1.251. A copy of this notice should be included with the reply.

The enclosed papers are a complete and accurate copy of the above-identified papers.

Name: Kate H. Murashige Registration No.: 29,959

Signature: Kate H. Murashige Date: April 9, 2002 DOCKETED Resp Due

REMINDER: 4/3/02

DUE DATE: _____

FINAL DUE DATE: _____ 3/19/02 8:39 AM

Docket N .: 205032000420	Atty: Kate H. Murashige
Serial N .: Not yet assigned	Filing Date: Herewith
Title: ADENOSINE AS ANTITHROMBOTIC	
Date of Mailing: May 10, 2001	

Papers enclosed herewith:

1. Fee Transmittal (1 page, 1 duplicate)
2. Transmittal (1 page)
3. CIP patent application specification (17 pages)
4. Drawings, informal (12 pages)
5. Combination POA/Declaration, signed (3 pages)

6. Application Data Sheet (2 pages)
7. Postcard

RECEIVED BY THE UNITED STATES PATENT AND TRADEMARK OFFICE
VIA EXPRESS MAIL EL719481935US ON May 10, 2001

PTO/SB/05 (11-00)

Valid for use through 10/31/02. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 205032000420

First Inventor Su-Chen Chang, et al.

Title ADENOSINE AS ANTITHROMBOTIC

Express Mail Label No. EL719481935US

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL719481935US

Date of Deposit: May 10, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

K. S. Huff

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. Fee Transmittal Form (e.g. PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. Applicant claims small entity status.
See 37 CFR 1.27.
3. Specification [Total Pages 17]
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. Drawing(s) (35 USC 113) [Total Sheets 12]
5. Oath or Declaration [Total Pages 3]
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 CFR 1.63(c))
(for continuation/divisional with Box 17 completed)
 - i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.63(b)
6. Application Data Sheet. See 37 CFR 1.76

ADDRESS TO:
Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. CD-ROM or CD-R (2 copies); or
 - ii. paper
 - c. Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers
10. 37 CFR 3.73(b) Statement
(where there is an assignee)
11. English Translation document (if applicable)
12. Information Disclosure Statement
(IDS)/PTO-1449
13. Preliminary Amendment
14. Return Receipt Postcard (MPEP 503)
Should be specifically requested
15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. Request and Certification under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. Other

18. If a CONTINUATING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Continuation Divisional Continuation-in-part (CIP)

of prior application No: 09/708,306 filed November 7, 2000.

Prior application information:

Examiner

Group / Art Unit:

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. This incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

 Customer Number or Bar Code Labelor Correspondence address below

25225

PATENT TRADEMARK OFFICE

(Insert Customer No. or Attach bar code label here)

Name	KATE H. MURASHIGE		
	MORRISON & FOERSTER		
Address	3811 VALLEY CENTRE DRIVE, SUITE 500		
City	SAN DIEGO	State	CA
Country	USA	Telephone	(858) 720-5112
Name (Print/Type)	KATE H. MURASHIGE	Registration No. (Attorney)	29,959
Signature			Date May 10, 2001

PTO/SB/17 (09-00)

Approved for use through 10/31/2002. OMB 0651-0052
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL FOR FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$765.00)

Attorney Docket No.

205032000420

Complete If Known

Application Number	Not yet assigned, parent 09/708,308
Filing Date	HEREWITH
First Named Inventor	Su-Chen Chang
Examiner Name	Not yet assigned
Group Art Unit	Not yet assigned

METHOD OF PAYMENT

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:
- Deposit Account Number: 03-1952
- Deposit Account Name: Morrison & Foerster LLP
- Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17
- Applicant claims small entity status. See 37 CFR 1.27
2. Payment Enclosed:
- Check Credit Card Money Order Other

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	85	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	185	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions of the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per properties (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))	
179	710	279	355	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

Complete (if applicable)

SUBMITTED BY

Name (Print/Type)	Kate H. Murashige	Registration No. (Attorney/Agent)	29,959	Telephone	(858) 720-5112
Signature	<i>Kate H. Murashige</i>				

** or number previously paid, if greater; For reissues, see above.